For more than a decade, the Food and Drug Administration (FDA) has made diversity in clinical trials a focus, including by issuing guidance, ...

Multiple federal health agencies have stopped releasing some key health information — including updates on some outbreak investigations — amid a department-wide communications "pause" ordered by the ...

The FDA announced its draft guidance on recommendations for studies ... Panelists at an FDA Medical Devices Advisory Committee meeting in 2022 previously pointed out that pulse oximeters show ...

Amid a deluge of executive actions, the Trump administration has directed federal health agencies to pause external ...

The FDA removed previously issued draft guidance on diversity in clinical trials from its website without public notice or ...

FDA’s guidance emphasizes the importance of transparency ... s AI experts and in-house counsel to ensure a sponsor is meeting all of FDA’s requirements to move a product to market.

The website changes raise concerns about “the interference of politics with the study and the practice” of science and ...

FDA Inspections Seminar: Fundamentals and the Ground Rules on How to Prepare for and Survive an FDA Inspection (ONLINE EVENT: February 24-25, 2025) Research and Markets Thu, Jan 30, 2025, 7:12 AM ...

Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company focused on delivering therapeutics through effective oral delivery, announced today that it has received revised regulatory guidance for LPCN ...